Rallybio Corp

Rallybio Corp (RLYB) priced its initial public offering on Jul 30, 2021 at $13.00 per share, within its $13.00–$15.00 range, raising $80.6M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $405.6M. Jefferies was lead-left underwriter, joined by TD Cowen and Evercore ISI. Ropes & Gray advised the company and WilmerHale advised the underwriters.

Rallybio Corp is a clinical-stage biotechnology company developing therapies for severe and rare diseases. Since its launch in January 2018, it has acquired a portfolio of five programs.

Status

IPO

Ticker

RLYB

Exchange

Nasdaq Global Select

Priced

Jul 30, 2021

IPO price

$13.00

Price range

$13.00–$15.00

Raised

$80.6M

Market cap at IPO price

$405.6M

First filed

Jul 2, 2021

Underwriters

Jefferies, TD Cowen and Evercore ISI

Company counsel

Ropes & Gray

Underwriters' counsel

WilmerHale

Sector

Biotech & pharma

Country / state

CT

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.